Developing with a Forward-Looking Vision, Dancing with the Wind to Showcase Elegance - 2021 Annual Work Summary and Commendation Conference

In today's world, the development of the biopharmaceutical industry is unstoppable. Whoever seizes the opportunity of the biopharmaceutical era and occupies the commanding heights of future development can achieve overtaking on a curve, shift gears to accelerate, and leapfrog ahead. Jiangxi Bio is currently at a critical stage of accumulation and breakthrough, listing development, and transformation and upgrading. Vigorous development is the only way for the company to adapt to the new round of technological revolution and industrial transformation. It is an inevitable requirement to implement the goal positioning of "setting an example and striving to be first" and an important ignition point to promote the company's high-quality leapfrog development. To further summarize and accelerate, Jiangxi Bio held the 2021 annual work summary and advanced commendation conference grandly at 3 p.m. on January 25, 2021, in the third-floor training center, where all employees gathered happily. The company's controlling shareholder representative Mr. Xiao Ying, Chairman Liu Yurui, General Manager Yao Xiaodong, and senior executives at home attended. The office conducted a live broadcast in the "Jiangsheng Home" WeChat group.

The meeting was first opened by the company's Executive Vice President Hu Xiande, who read the "2021 Annual Company Work Summary Report" on behalf of the management team. The report summarized that in 2021, all employees earnestly implemented the spirit of the annual work meeting at the beginning of the year, carried forward the spirit of innovation and progress, and strived to overcome difficulties such as the pandemic and rising prices. Everyone participated in new technological transformations, vigorously promoted the IPO, expanded external platforms to enhance the company's image, organized supply to ensure production, refined management to improve quality, opened new sources and cut costs, and pushed R&D to new heights, boldly pioneering and innovating to achieve remarkable results. The report was divided into five parts, reporting the main work achievements and key measures in 2021, focusing on market development and management efforts, high-end R&D talent, internal control system construction, human resource composition, and other issues. It carefully analyzed these problems and formulated reform measures such as adjusting the marketing management structure, optimizing the marketing team; strengthening production capacity assurance and improving production efficiency; enhancing the quality system; ensuring supply, reducing costs, improving financial staff skills, enhancing overall professional quality, developing talent reserves, and improving the company management system. It proposed that in 2022, the company will always implement the overall goal of "improving quality, creating brands, seizing markets, becoming leaders, increasing efficiency, and listing on the main board," with the main line of "improving management quality and standardizing management behavior," promoting the construction of a new development pattern centered on Jiangxi Bio's large circulation, with medical aesthetics, pharmaceuticals, and dual circulation of agriculture, animal husbandry, and veterinary medicine mutually promoting each other. The focus will be on product upgrades and technological innovation, with the principle of "focusing on people's needs and caring for patients' requirements," to solidly promote "Gansu quality products," optimize and lead "Jiangxi famous brands," and effectively connect company development with listing. With the concept of high-quality leapfrog development, the company will refine and perfect its distinctive advantages in antitoxin and immune serum products. Broad consensus will be gathered to draw the largest concentric circle, making "setting an example, striving to be first, and being a benchmark" more motivating, employees more effective in their duties, and Jiangxi Bio's image more distinctive. The company will strive to demonstrate Jiangxi Bio's responsibility, show its role, and make contributions in the new pattern of innovation and excellence.

The company's Vice General Manager Mr. Ji Chong read the commendation notice for advanced collectives and individuals in 2021. Company leaders presented certificates of honor and bonuses to one advanced collective, one outstanding contribution awardee, one special contribution awardee, 14 advanced workers, 4 technological transformation model workers, and 3 IPO model workers. Everyone was encouraged to learn from their dedication to their posts, compliance with rules and discipline, obedience to management, and teamwork spirit; to learn from their sincere, pragmatic, and dedicated professional ethics; and to learn from their down-to-earth, hardworking, and diligent work style.

The company's General Manager Mr. Yao Xiaodong further summarized experiences from a strategic height and put forward new requirements and goals. In an extraordinary year, all employees were busy and fulfilled, winning more than 10 honors such as Jiangxi Province Excellent Enterprise, Gansu Quality Products, and Jiangxi Province Famous Brand Products. These achievements and honors will play a huge role in promoting the company's IPO work and development. The company successfully passed five provincial and municipal platform approvals, including the provincial specialized and new "little giant" expert approval, laying a solid foundation for applying for the national specialized and new "little giant" status. The platform application achieved remarkable results and played a good leading role in enhancing the company's external image. The Xilin bottle technological transformation project was successfully completed, laying a solid foundation for the company's subsequent development. After years of effort, the progress of new technology and new product R&D has accelerated. The company's new products, such as freeze-dried human rabies vaccine, snake venom serum, and COVID-19 serum, have promising development prospects, opening a new chapter for the company to enter the vaccine industry. The IPO work has welcomed law firms, accounting firms, and intermediaries, entering the accelerated and critical stage of listing, laying a solid foundation for entering the capital market in 2022. These five achievements are the result of everyone's joint efforts, the best return to investors, and the company's development inevitability. With many competitors, we must clearly recognize five major shortcomings: sales decline, imperfect internal control system, lagging informatization construction, need for improved management standardization, and shortage of high-end talent. We must enhance our sense of mission, urgency, and crisis, find breakthroughs and focus points, work precisely and meticulously, and develop the company's economy comprehensively and systematically, striving to secure the "due position" on the national map. At the meeting, General Manager Yao Xiaodong deployed key tasks for 2022, including improving product sales, accelerating technological transformation registration, speeding up R&D project implementation and transformation, promoting the IPO process, and strengthening informatization construction. In 2022, the company will closely focus on the 18-character overall goal of "improving quality, creating brands, seizing markets, becoming leaders, increasing efficiency, and listing on the main board," with the main line of "improving management quality and standardizing management behavior," breaking through problems with new ideas, adopting multiple measures, and forging ahead with new combat power, spirit, and work style to promote the strategic innovation and leapfrog development of the joint-stock company, striving to make new contributions in the pattern of innovation and excellence. Finally, New Year blessings and best wishes were extended to all employees.

The Chairman of the Joint-Stock Company, Mr. Liu Yurui, comprehensively interpreted the work achievements over the past year from the perspectives of company development and listing, boosting the confidence of all employees and outlining a higher, longer-term development vision for the company. Chairman Liu Yurui sincerely congratulated the advanced departments and individuals who were commended and expressed heartfelt thanks to employees working hard in various positions. In the new year, the company will focus on technological innovation, accelerate technological innovation and talent team building, and create a "rainforest" economic new ecosystem. The company must grasp the "bull's nose" of independent innovation, strive to create provincial and national technology innovation platforms, precisely implement key technology tackling actions, and strive to form more core technologies with independent intellectual property rights; improve the innovation incentive mechanism, promote talent attraction, retention, and effective utilization, and let the company experience a talent surge. It is hoped that all employees will continuously improve themselves and the company's overall strength, advancing the implementation of annual work goals with new outlooks, new goals, and new measures, striving to create a new situation of rapid company development.

The controlling shareholder representative Mr. Xiao Ying brought investors' earnest hopes and best wishes for the company's development. He conveyed the boss's New Year blessings to all employees of Jiangxi Bio, hoping that in the new year, everyone will deeply implement the company's overall goals, focus on key areas, precisely cultivate industrial tracks, and accelerate the cultivation of new industrial advantages. The key to optimizing and strengthening biopharmaceuticals lies in strengthening the engine, not only doubling the "quantity" but also achieving a "quality" leap. Supporting the company's high-quality rapid development, pursuing perfection, creating excellence with a new posture, working more solidly, doing every task with care, continuously creating new heights, and working together to realize the Jiangxi Bio dream.

The company's development potential is limitless, and Jiangsheng's future is full of hope! Let us firmly seize the era's opportunities for company development, strengthen our confidence, strive diligently, and persevere unwaveringly. Aim for a first-class "coordinate system," implement first-class "strong measures," and strive for first-class "excellent results" to promote the company's economic leapfrog development and vigorously create a new realm of high-quality leapfrog development.